Advanced Urothelial Carcinoma
Advertisement
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
PIVOT-10 expanded on PIVOT-02 by further investigating BEMPEG with nivolumab in cisplatin-ineligible patients.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.